284 results about "Low toxicity" patented technology

The invention discloses application of tannic acid combined triazole medicines in preparation of medicines for treating diseases caused by fungi, and belongs to the technical field of antifungal. A series of drug sensitive tests show that tannic acid lower than 3 [mu] g / ml has no influence on the activity of human vaginal epithelial cells, and after the tannic acid is combined with fluconazole, the tannic acid can significantly inhibit the growth activity of drug-resistant candida (including drug-resistant candida albicans and drug-resistant candida glabrata). In view of the natural property, wide source and low toxicity of tannic acid, the invention provides a new antifungal treatment strategy, and the tannic acid has important clinical application value for treating infection (such as vaginal candidiasis) caused by drug-resistant fungi, especially under the condition that the existing antifungal drugs are poor in effect. Therefore, the tannic acid combined triazole medicine can be used for preparing the medicine for treating diseases caused by fungi.

The invention discloses a polypeptide with a whitening effect and a preparation method and application thereof.The polypeptide is obtained from hydrolyzed protein of babylonia areolata, the amino acid sequence of the polypeptide is cysteine-arginine-proline-threonine-cysteine-serine-arginine-leucine-alanine-cysteine, and the amino acid sequence of the polypeptide is cysteine-arginine-proline-threonine-cysteine-serine-arginine-leucine-alanine. The compound can obviously inhibit the generation of melanin in cells and the activity of tyrosinase in vitro, has the characteristics of low toxicity, low irritation, good stability, safety and high efficiency, and can be applied to whitening cosmetics.

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or derivatives thereof or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating polycystic ovarian syndrome (PCOS). The beta-elemonic acid is screened from a medicinal and edible library, and experiments prove that the beta-elemonic acid can remarkably improve the PCOS ovarian form and the number of mature follicles, normalize the disordered estrus cycle, remarkably improve the serum hormone level and further remarkably improve the sugar tolerance, insulin tolerance and weight of PCOS. The beta-elemonic acid disclosed by the invention is a compound based on homology of medicine and food, can be used as a medicine as well as a natural ingredient of food, is relatively low in toxicity, ensures the safety after long-term use, is relatively low in safety evaluation cost of a relatively brand-new synthetic compound, and can be applied to development and preparation of a medicine or a lead compound thereof for preventing and / or treating PCOS, or a health care product.

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

The invention provides an application of a polypeptide Nod-T3 in preparation of a medicine for treating lung diseases, the polypeptide Nod-T3 is derived from human protein, has the effect of remarkably inhibiting chronic lung inflammation and fibrosis caused by smoking, can be used for treating COPD and other smoking-related lung diseases, and is high in biocompatibility, small in toxicity, low in cost and suitable for clinical application. The polypeptide has the potential and development value of becoming a novel polypeptide drug.

The invention belongs to the technical field of urine wastewater treatment, and particularly discloses a novel corrosion-resistant slow-release product for urine wastewater and a preparation method of the novel corrosion-resistant slow-release product. Sucrose, isomaltitol, a Kathon solution, citric acid, sorbic acid, benzoic acid and sodium benzoate are used as main raw materials to prepare a sustained-release product. The slow-release product has the effects of preventing corrosion and odor of urine. The slow-release block can effectively inhibit hydrolysis of urea in urine wastewater, and has good corrosion-resistant and odor-resistant effects; the hardness is higher, and powder is not easy to crack after long-time storage; the dissolvability is good, the toxicity is low and the environment-friendly effect is realized. The method is simple in preparation process flow, high in repeatability, low in equipment requirement, low in production cost and easy for industrial batch production.

The invention discloses a benzodiazepine # imgabs0 # compound with a structure as shown in a formula I or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorphic substance, a solvate, a metabolite or a prodrug of the benzodiazepine # imgabs0 # compound. The benzodiazepine # imgabs 1 # compound disclosed by the invention has the characteristics of low toxicity, high safety, quick action, short action time, stable anesthesia, quick metabolism, quick reviving and the like. The invention further discloses application of the benzodiazepine # imgabs2 # compound or pharmaceutically acceptable salt, stereoisomer, tautomer, polymorphic substance, solvate, metabolite or prodrug thereof in preparation of sedative or anesthetic drugs, and further discloses application of the benzodiazepine # imgabs2 # compound or pharmaceutically acceptable salt, stereoisomer, tautomer, polymorphic substance, solvate, metabolite or prodrug thereof in preparation of sedative or anesthetic drugs. # imgabs3 #

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

The invention discloses a solvent type cleaning agent for replacing dichloromethane, which is characterized by comprising the following components in parts by weight: 70-90 parts of hydrocarbon solvent D40; 0 to 15 parts of chlorinated methoxy fatty acid methyl ester; and 0-15 parts of butanediol diacetate, wherein the number of parts of the chloro-methoxy fatty acid methyl ester or butanediol diacetate is not 0 at the same time. Compared with the existing dichloromethane cleaning agent, the cleaning agent disclosed by the invention has the advantages of low toxicity, low volatilization amount, no corrosivity, low VOC (Volatile Organic Compounds), certain anti-rust capability and no key control pollutant CFC113, carbon tetrachloride and trichloroethylene.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.

The invention relates to application of salvianolic acid B in preparation of anti-inflammatory and anti-radiation drugs. Experimental verification shows that within a safe concentration range, salvianolic acid B can effectively inhibit the release amount of NO in RAW264.7 cells and the expression level of proinflammatory factors TNF-alpha, IL-6, IL-1beta and IFN-gamma in the RAW264.7 cells under the co-stimulation of LPS and radiation, and meanwhile, the phagocytic ability of the cells is improved; the salvianolic acid B remarkably inhibits the H2O2 expression level of RLE-6TN cells and relieves the early apoptosis of the RLE-6TN cells, and the results show that the salvianolic acid B can be used for preparing the anti-inflammatory and anti-radiation drugs. Compared with a traditional clinical medicine, the salvianolic acid B has the advantages of low toxicity and low side effect as a natural traditional Chinese medicine product.

The invention discloses application of pseudo-ginseng external vesicles in preparation of drugs for preventing and treating or improving heart diseases. The plant exovesicle provided by the invention has the advantages of low toxicity, high biocompatibility, biodegradability, no induction of immunogenicity, high yield and large-scale preparation. A large number of experimental studies prove that the pseudo-ginseng external vesicles disclosed by the invention have a remarkable heart disease prevention and treatment effect. Therefore, development and application of the fresh pseudo-ginseng medicine are promoted.

The present invention relates to a lipid pre-concentrate and a method for preparing same, wherein the lipid pre-concentrate uses a biodegradable lipid having low injection force and low toxicity to delay the release rate of a drug, thereby exhibiting sustained release so that the administered drug can be continuously released for a long period of time.

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

The invention relates to the technical field of medicines, and particularly discloses application of a Xinjiang medicine mulberry extract in preparation of a medicine for treating or preventing periapical periodontitis, which is technically characterized in that the Xinjiang medicine mulberry extract is found and proved to have a remarkable inhibition effect on periapical periodontitis key pathogenic bacterium enterococcus faecalis for the first time, the minimum inhibitory concentration (MIC) is 0.604 mg / mL, and the Xinjiang medicine mulberry extract has a remarkable inhibition effect on the periapical periodontitis key pathogenic bacterium enterococcus faecalis. The minimum bactericidal concentration (MBC) is 1.875 mg / mL, and a biological membrane can be effectively inhibited and removed; in-vivo experiments of a rat periapical periodontitis model prove that the extract can remarkably reduce the number of bacteria in root canals and relieve periapical bone destruction, the curative effect is equivalent to that of calcium hydroxide, and the extract is non-toxic to main organs and high in biocompatibility. The invention provides a new candidate and a clear technical scheme for developing an efficient and low-toxicity natural plant source root canal disinfectant.

The present invention belongs to the field of biological fermentation technology, and relates to an exosome derived from beer fermentation broth, and a preparation method and application thereof. The present invention provides an exosome derived from beer fermentation broth, and uses beer fermentation broth as a raw material to extract exosomes to obtain exosomes derived from beer fermentation broth. The present invention utilizes beer puree to enrich exosomes, which has the characteristics of low cost, easy acquisition, low toxicity, high yield, high biocompatibility and safety. It can be used as a functional exosome and a drug delivery carrier for the treatment of tissue damage repair and neurodegenerative diseases, etc., and has broad application prospects.

This invention provides a drug-coated balloon catheter, its preparation method, and its application, relating to the field of medical device technology. The drug-coated balloon catheter includes a balloon catheter and a drug coating disposed on the surface of the balloon catheter; the drug coating includes an active drug and an excipient; the active drug is a flavonoid. The drug-coated balloon catheter utilizes flavonoids, which combine the advantages of low toxicity and high water solubility. While reducing the toxic side effects of the drug coating, it achieves rapid release and efficient absorption of the drug. Furthermore, through a dual mechanism of anti-proliferation and anti-inflammation, it effectively solves the problems of potential toxic side effects, limited transport efficiency, and limited functionality that may exist in existing products at high dose densities.

A benzofuran-based N-acylhydrazone derivative according to the present invention has an excellent anticancer effect while having low toxicity and excellent solubility, and thus a pharmaceutical composition comprising the derivative can be usefully used to prevent or treat a cell proliferative disorder including various cancers.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

The present invention provides a formylpiperidine compound, a preparation method and an application thereof. The general structural formula of the formylpiperidine compound is shown in formula (I), or its isomer, or its pharmaceutically acceptable salt, ester or prodrug. The formylpiperidine compound described in the present invention is a dual-target inhibitor of 5-HT reuptake and 5-HT 1A receptor, which can overcome the problems of low clinical efficacy, poor metabolic stability and poor safety of existing antidepressant drugs, and is a compound with a novel structure, high efficiency, stability and low toxicity and having an antidepressant effect.

The invention provides a preparation method and application of amino acid derived carbon dot nano-enzyme, and belongs to the technical field of new biomedical materials. The amino acid comprises one of histidine, proline, cysteine, tryptophan, aspartic acid, arginine, lysine, methionine and phenylalanine; the mass ratio of the amino acid to the citric acid monohydrate is (1: 1)-(1: 5). The amino acid derived carbon dots provided by the invention have free radical scavenging activity and superoxide dismutase-like properties, and show low toxicity and good biological safety at the levels of cells, nematodes and animals. Meanwhile, the amino acid derived carbon dot nano-enzyme also shows excellent anti-inflammatory activity, can down-regulate the inflammatory level of cells, reduce the damage of oxidative stress to nematodes, improve the intestinal flora structure, increase the richness and diversity of intestinal flora, relieve and treat DSS-induced mouse ulcerative colitis, and has a good application prospect. The compound can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention discloses an aromatic propionic acid derivative as well as a preparation method, a pharmaceutical composition and application thereof. The invention specifically discloses a compound shown in a formula (I) or pharmaceutically acceptable salt thereof. The invention further discloses a pharmaceutical composition which comprises the compound shown in the formula (I), pharmaceutically acceptable salt of the compound and pharmaceutic adjuvants. The invention also discloses application of the compound as shown in the formula (I), the pharmaceutically acceptable salt of the compound or the pharmaceutical composition in preparation of drugs, and the drugs have GPR40 receptor agonistic activity and have one or more of the advantages of good activity, high targeting property, low toxicity and the like. # imgabs0 #

The invention discloses an electrochemical polishing solution for laser additive manufacturing of a tantalum material and a preparation method and process, and relates to the technical field of surface treatment of metal workpieces. According to the electrochemical polishing solution, an alcohol-salt system is adopted for electropolishing treatment, and compared with a traditional electropolishing solution, the electrochemical polishing solution has the advantages of electrochemical and chemical stability, relatively high conductivity, relatively high controllability, relatively low toxicity, low volatility, environment friendliness and the like; the electropolishing solution has the characteristics of no volatilization, no odor, low toxicity to a human body and the like by adding the inorganic solid acid formed by replacing sulfamic acid sulfuric acid hydroxyl with amino, and not only has the oxidation capacity of sulfuric acid, but also can promote dissolution and improve the material removal rate by the amino; the electrochemical polishing solution is mild in process parameter, insensitive to temperature, capable of implementing polishing at room temperature, small in corrosion to electrolysis equipment and capable of being used for a long time.

The invention belongs to the technical field of preparation of anti-inflammatory drugs, and particularly discloses a tryptanthrin derivative and a preparation method and application thereof.The structural formula of the tryptanthrin derivative is # imgabs0, R is one of R1, R2 and R3, and when R is R1, # imgabs1 # reacts with H-R1, Pd (PPh3) 2Cl, copper iodide, triethylamine and an organic solvent to prepare the tryptanthrin derivative; when R is R2, the catalyst is prepared by reacting # imgabs2 # with H-R2, Pd2 (dppf) Cl2, potassium acetate and methylbenzene; when R is R3, the PdCl (PPh3) 4 is prepared by reacting with H-R3, silver carbonate, PdCl (PPh3) 4 and acetonitrile. The tryptanthrin derivative disclosed by the invention has high biological activity and solubility and low toxicity, and has the potential of being developed into a medicine for treating ulcerative colitis.

The present invention provides a method for preparing and applying amino acid-derived carbon dot nanozymes, belonging to the field of new biomedical materials technology. The amino acid comprises one of histidine, proline, cysteine, tryptophan, aspartic acid, arginine, lysine, methionine, and phenylalanine; the mass ratio of the amino acid to citric acid monohydrate is 1:1 to 1:5. The amino acid-derived carbon dots proposed in the present invention have free radical scavenging activity and superoxide dismutase-like properties, exhibiting low toxicity and good biosafety at the cellular, nematode, and animal levels. Furthermore, the amino acid-derived carbon dot nanozymes exhibit excellent anti-inflammatory activity, downregulating cellular inflammation, reducing oxidative stress damage to nematodes, improving intestinal flora structure, increasing the richness and diversity of intestinal flora, and alleviating and treating DSS-induced ulcerative colitis in mice. The nanozymes can be further applied to the preparation of drugs for treating inflammatory bowel disease.

The invention relates to the technical field of hydrogel, in particular to medical composite hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: compounding attapulgite powder and transition metal sulfide under a high-temperature condition by adopting a hydrothermal method to form a TMDC / PGS composite material; the content of the TMDC in the TMDC / PGS composite material is 90 to 97.5 weight percent; mixing the hydrogel solution with a TSPBA solution to obtain a reaction base solution; and adding the TMDC / PGS composite material into the reaction base solution, and treating under heating and ultrasonic conditions to obtain the medical composite hydrogel. The medical composite hydrogel disclosed by the invention not only has the characteristics of injectability, low toxicity and antibacterial property, but also has the functions of promoting wound healing, promoting epidermis, blood vessel and nerve regeneration, resisting inflammation and resisting oxidation, and is particularly suitable for promoting wound repair of diabetic patients.

Disclosed is an mIDH1 / NAMPT dual-target inhibitor, which is selected from a compound having a structure as shown in formula (I) or formula (II), or a pharmaceutically acceptable salt, racemate, stereoisomer, prodrug, or solvent compound thereof. The dual-target inhibitor of the present invention can effectively overcome the shortcomings of a single mIDH1 inhibitor and single NAMPT inhibitor having poor efficacy against solid tumors. Said inhibitor can inhibit the malignant proliferation of tumors, has a good therapeutic effect, has low toxicity, and can penetrate the blood-brain barrier, and it is not easy to acquire drug resistance to said inhibitor. Moreover, the inhibitor can be used to prepare a medicament for treating cancer or tumor-related diseases, the cancer or tumor-related diseases comprising multiple myeloma, leukemia, breast cancer, prostate cancer, lung cancer, liver cancer, gastric cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer, and endometrial cancer.

The invention discloses multifunctional selenium nanoparticles for treating inflammatory bowel diseases as well as a preparation method and application of the multifunctional selenium nanoparticles, and relates to the technical field of biological medicines. The multifunctional selenium nanoparticle is of a core-shell structure and comprises an inner core and an outer layer coating the inner core, the inner core is selenium nanoparticles; and the outer layer is a polydopamine shell embedded with chitosan oligosaccharide. The multifunctional selenium nanoparticles provided by the invention have good stability and dispersibility, can target intestinal inflammation parts, prolong the in-vivo time of the nanoparticles, and show strong antioxidant and anti-inflammatory activity on cell and animal levels. The whole nanoparticle is based on low toxicity and colon targeting of a natural material, is higher in safety compared with a traditional glucocorticoid / biological preparation, relieves intestinal inflammation by adjusting a redox steady state, prolonging drug action time and the like, and is expected to become a novel colitis treatment strategy with high efficiency, targeting property and safety.

The invention discloses an oral medicine composition containing olopatadine hydrochloride and a preparation method of the oral medicine composition, and relates to the technical field of pharmaceutical preparations, and the oral medicine composition is prepared from the following components in percentage by weight: 0.5-1.5% of modified olopatadine hydrochloride nanocrystals, 0.05-0.1% of xanthan gum, 0.03-0.05% of an antioxidant, 0.5-1.5% of a flavoring agent, 0.1-0.3% of olopatadine hydrochloride-containing lipidosome and 5-10% of other auxiliary materials, and the balance of purified water. The oral medicine composition is obvious in medicine effect, low in toxic and side effects, good in taste, good in controlled release and stability and high in bioavailability.